VacZine Analytics  
MarketVIEW: Alzheimer's disease vaccines

Published: January 2013

Alzheimer's Diseaseis the most common form of dementia first described by German neurologist Alois Alzhemier in 1906. It is an irreversible, progressive brain disease that destroys cognitive skills such as memory and thinking ability rendering sufferers unable to carry out even simple tasks. In 2010, there were an estimated 35.6m people living with dementia worldwide of which Alzheimer's disease accounted for 60-70% of cases. There is currently no cure for Alzheimer's disease and treatments are concentrated on the management of symptoms.

This MarketVIEW is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of Alzheimer's vaccines across major Western markets until 2030. The model contains value ($ m) and volume (mio doses) predictions per product type (therapeutic + prophylatic) along with timeframe, pricing and penetration estimates for all adult risk groups depending on Alzheimer's disease severity. The product also includes an up-to-date review of disease epidemiology and competitor R&D pipeline activity.

THIS PRODUCT IS A EXECUTIVE PRESENTATION + 1 MODEL

To order please contact your region account manager, buy "on-line" or order direct at: orders@vaczine-analytics.com

CAT No: CONTENTS: PURCHASE:
VAMV041 Click here>>
Discounted option:
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW. For UK orders VAT will be added at 20%. Please review the TERMS and CONDITIONS of purchase.

Return to main list>> Questions about this report?






© 2013 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains